Therapeutic Asset Ratings

13,155 results matching 1 filter

91,564 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Fludarabine Malignant Peripheral Nerve Sheath Tumor	St. Jude Children's Research Hospital	P2	B (59)
Fludarabine Metastatic Malignant Neoplasm	Beijing Biotech	P2	B (59)
Fludarabine Ocular Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P2	B (59)
Fludarabine Primary Peritoneal Carcinoma	Beijing Biotech	P2	B (59)
Fludarabine Small Intestine Cancer	National Cancer Institute (NCI)	P2	B (59)
Fludarabine Squamous Cell Lung Carcinoma	Intima Bioscience, Inc.	P2	B (59)
Fludarabine T Lymphoblastic Leukemia/Lymphoma	First Affiliated Hospital of Zhejiang University	P2	B (59)
Fludeoxyglucose Metastatic Prostate Carcinoma	University of Wisconsin, Madison	P2	B (59)
Fluzoparib Small Cell Lung Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	B (59)
Fluzoparib Triple-Negative Breast Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	B (59)
Gvax Pancreas Vaccine Pancreatic Neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (59)
her3-dxd Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P2	B (59)
hs-10380 Schizophrenia	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P2	B (59)
Hydroxychloroquine Prostate Cancer	Lionel.D.Lewis, MD	P2	B (59)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Cutaneous Neuroendocrine Carcinoma	University of Zurich	P2	B (59)
Imatinib Melanoma	University of California, San Francisco	P2	B (59)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine) Mantle Cell Lymphoma	National Cancer Institute (NCI)	P2	B (59)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Esophageal Adenocarcinoma	University of California, Irvine	P2	B (59)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Primary Peritoneal Carcinoma	Regeneron Pharmaceuticals	P2	B (59)
Indoximod Glioblastoma	Theodore S. Johnson	P2	B (59)
Infliximab Cutaneous Melanoma	Therakos LLC	P2	B (59)
Ipilimumab Anal Carcinoma	National Cancer Institute (NCI)	P2	B (59)
Ipilimumab Breast Carcinoma	Emory University	P2	B (59)
Ipilimumab Urinary Bladder Small Cell Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P2	B (59)
Ipilimumab Bladder Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	B (59)

Showing 2326 to 2350 of 13,155 assets

PreviousPage 94 of 527Next